Cited 0 times in 
Cited 0 times in 
A Prospective Paired Comparison Trial of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Son, Hee Seo | - |
| dc.contributor.author | Kim, Jang Hwan | - |
| dc.date.accessioned | 2025-12-02T06:35:12Z | - |
| dc.date.available | 2025-12-02T06:35:12Z | - |
| dc.date.created | 2025-11-21 | - |
| dc.date.issued | 2025-09 | - |
| dc.identifier.issn | 2093-4777 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/209253 | - |
| dc.description.abstract | Purpose Low bladder compliance (BC) poses a significant clinical challenge. Nevertheless, studies exploring pharmacological mechanisms to improve BC remain limited. We investigated the efficacy of a beta 3-adrenoceptor agonist, mirabegron, on BC in comparison with anticholinergics. Methods This prospective single-arm paired comparison trial included 14 patients with low BC (<= 20 mL/cm H2O) despite anticholinergics treatment. After a 2-week anticholinergics-washout period, patients were treated with mirabegron for 8 weeks and then returned to 8 weeks of anticholinergics. Major treatment effect was assessed with urodynamic studies performed at baseline, 8 weeks after mirabegron treatment, and 8 weeks after consecutive anticholinergics treatment (McNemar test, Paired t-test; mean [95% confidence intervals]). Results Following mirabegron, 71.43% of patients exhibited a BC of >20 mL/cm H2O, compared to 54.55% after switching back to anticholinergics (P=0.317). BC improved significantly from 12.02 (9.52-14.52) to 39.67 (21.60-57.73) mL/cm H2O after mirabegron treatment (P=0.007), but subsequently declined to 20.94 (15.78-26.10) mL/cm H2O after reintroduction of anticholinergics (P=0.075). Maximum cystometric capacity increased from 352.21 (282.78-421.65) to 442.71 (348.95-536.48) mL after mirabegron (P=0.091), but decreased to 402.00 (315.92-488.08) mL after returning to anticholinergics (P=0.218). Notably, detrusor pressure at end-filling decreased significantly with mirabegron, from 30.50 (25.61-35.39) to 14.43 (10.79-18.06) cm H2O (P<0.001), while increasing to 20.36 (16.26-24.46) cm H2O after returning to anticholinergics (P=0.056). Conclusions A beta 3-adrenoceptor agonist, mirabegron, was more effective than anticholinergics in improving BC. Among the two components of improved BC-increased bladder volume and reduced detrusor filling pressure-the beta 3-adrenoceptor agonist showed a more pronounced effect on lowering detrusor filling pressure, compared to anticholinergics. These findings suggest that beta 3-adrenoceptor agonists might play an important role in reducing the tension of the bladder wall by controlling detrusor muscle tone, and this may be an important target for future research. | - |
| dc.description.statementOfResponsibility | open | - |
| dc.language | English | - |
| dc.publisher | Korean Continence Society | - |
| dc.relation.isPartOf | INTERNATIONAL NEUROUROLOGY JOURNAL(대한배뇨장애요실금학회지) | - |
| dc.rights | CC BY-NC-ND 2.0 KR | - |
| dc.title | A Prospective Paired Comparison Trial of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance | - |
| dc.type | Article | - |
| dc.contributor.college | College of Medicine (의과대학) | - |
| dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
| dc.contributor.googleauthor | Son, Hee Seo | - |
| dc.contributor.googleauthor | Kim, Jang Hwan | - |
| dc.identifier.doi | 10.5213/inj.2550050.025 | - |
| dc.relation.journalcode | J01171 | - |
| dc.identifier.eissn | 2093-6931 | - |
| dc.identifier.pmid | 41077793 | - |
| dc.subject.keyword | β3-adrenoceptor agonist | - |
| dc.subject.keyword | Cholinergic antagonist | - |
| dc.subject.keyword | Compliance | - |
| dc.subject.keyword | Detrusor muscle | - |
| dc.subject.keyword | Mirabegron | - |
| dc.subject.keyword | Muscle tone | - |
| dc.contributor.alternativeName | Kim, Jang Hwan | - |
| dc.contributor.affiliatedAuthor | Son, Hee Seo | - |
| dc.contributor.affiliatedAuthor | Kim, Jang Hwan | - |
| dc.identifier.scopusid | 2-s2.0-105017595833 | - |
| dc.identifier.wosid | 001586881500008 | - |
| dc.citation.volume | 29 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 197 | - |
| dc.citation.endPage | 206 | - |
| dc.identifier.bibliographicCitation | INTERNATIONAL NEUROUROLOGY JOURNAL, Vol.29(3) : 197-206, 2025-09 | - |
| dc.identifier.rimsid | 90181 | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.description.journalClass | 1 | - |
| dc.subject.keywordAuthor | β3-adrenoceptor agonist | - |
| dc.subject.keywordAuthor | Cholinergic antagonist | - |
| dc.subject.keywordAuthor | Compliance | - |
| dc.subject.keywordAuthor | Detrusor muscle | - |
| dc.subject.keywordAuthor | Mirabegron | - |
| dc.subject.keywordAuthor | Muscle tone | - |
| dc.subject.keywordPlus | BETA(3)-ADRENOCEPTOR AGONIST | - |
| dc.subject.keywordPlus | MUSCARINIC RECEPTORS | - |
| dc.subject.keywordPlus | OVERACTIVE BLADDER | - |
| dc.subject.keywordPlus | AFFERENT ACTIVITY | - |
| dc.subject.keywordPlus | SMOOTH-MUSCLE | - |
| dc.subject.keywordPlus | DETRUSOR | - |
| dc.subject.keywordPlus | MODULATION | - |
| dc.subject.keywordPlus | MODEL | - |
| dc.subject.keywordPlus | TONE | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART003251625 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
| dc.relation.journalResearchArea | Urology & Nephrology | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.